Table 3.
Longitudinal growth models of the association of dispositional and situational coping with BCPT symptom scale total
| Coping measure |
||||
|---|---|---|---|---|
| Random effects | DispAVOID Est. (SE) | DispAPPROACH Est. (SE) | SitAVOID Est. (SE) | SitAPPROACH Est. (SE) |
| Intercept | ||||
| Intercept | 0.67** (.22) | 0.51* (0.24) | 0.81*** (0.15) | 0.80*** (0.15) |
| Chemotherapya (ref=no) | 0.04* (.02) | 0.05* (0.02) | 0.04* (0.02) | 0.04* (0.02) |
| Endocrine therapya (ref=no) | ||||
| Estrogen antagonists | 0.04 (0.05) | 0.16 (0.09) | 0.04 (0.05) | 0.04 (0.05) |
| Aromatase inhibitors | 0.04 (0.05) | 0.04 (0.10) | 0.03 (0.05) | 0.03 (0.05) |
| Surgerya (ref=no) | 0.03 (0.02) | 0.03 (0.02) | 0.03 (0.02) | 0.03 (0.02) |
| Radiationa (ref=no) | −0.05* (0.02) | −0.05* (0.02) | −0.05* (0.02) | −0.05* (0.02) |
| Herceptina (ref=no) | −0.03 (0.04) | −0.20** (0.07) | −0.01 (0.05) | −0.02 (0.05) |
| Stage | 0.01 (0.02) | 0.01 (0.02) | −0.00 (0.02) | 0.00 (0.02) |
| Employment (ref=employed) | ||||
| Retired | −0.07 (0.05) | −0.06 (0.05) | −0.08 (0.05) | −0.08 (0.06) |
| Unemployed | 0.15** (0.05) | 0.15** (0.05) | 0.15** (0.05) | 0.16*** (0.05) |
| Income | 0.06** (.02) | 0.06** (0.02) | 0.04* (0.02) | 0.04* (0.02) |
| Education | −0.04 (0.03) | −0.04 (0.03) | −0.01 (0.02) | −0.01 (0.02) |
| Married (ref=no) | 0.06 (0.04) | 0.07 (0.04) | 0.07* (0.04) | 0.06 (0.04) |
| Site (ref=Arizona) | 0.19*** (0.05) | 0.23*** (0.05) | 0.16 (0.04) | 0.20*** (0.04) |
| Age | −0.00 (0.00) | −0.00 (0.00) | −0.01*** (0.00) | −0.01*** (0.00) |
| Last treatment | 0.01 (0.02) | 0.01 (0.02) | 0.03* (0.01) | 0.03* (0.01) |
| Physical comorbidities | 0.05* (0.02) | 0.04 (0.02) | 0.06*** (0.01) | 0.06*** (0.01) |
| Coping | 0.08*** (0.02) | −0.12*** (0.02) | 0.15*** a (0.02) | 0.01a (.02) |
| Linear trajectory | ||||
| Intercept | 0.06 (0.06) | 0.13 (0.24) | 0.06 (0.06) | 0.06 (0.06) |
| Endocrine therapya (ref=none) | ||||
| Estrogen antagonists | −0.07* (0.03) | −0.08** (0.03) | −0.07** (0.03) | −0.07* (0.03) |
| Aromatase inhibitors | −0.01 (0.03) | −0.00 (0.04) | −0.01 (0.03) | −0.00 (0.03) |
| Herceptina (ref=no) | 0.06** (0.02) | 0.11*** (0.00) | 0.06 (0.02) | 0.06** (0.02) |
| Income | −0.01** (0.00) | −0.01** (0.00) | −0.01* (0.00) | −0.01* (0.00) |
| Education | 0.02* (0.01) | 0.02* (0.01) | 0.02* (0.01) | 0.02 (0.01) |
| Site (ref=Arizona) | −0.01 (0.01) | −0.01 (0.01) | −0.01 (0.01) | −0.01 (0.01) |
| Age | −0.00 (0.00) | −0.00* (0.00) | −0.00 (0.00) | −0.00 (0.00) |
| Last treatment | 0.01 (0.01) | 0.01 (0.01) | 0.01 (0.01) | 0.01 (0.01) |
| Physical comorbidities | 0.00 (0.01) | 0.01 (0.01) | 0.00 (0.01) | 0.00 (0.01) |
| Coping | 0.01** (0.00) | |||
| Quadratic trajectory | ||||
| Intercept | −0.02 (0.01) | −0.01 (0.01) | −0.01 (0.01) | −0.02 (0.01) |
| Endocrine therapya (ref=none) | ||||
| Estrogen antagonists | 0.01* (0.00) | 0.01* (0.00) | 0.01* (0.00) | 0.01* (0.00) |
| Aromatase inhibitors | 0.00 (0.00) | 0.00 (0.00) | 0.00 (0.00) | 0.00 (0.00) |
| Herceptina (ref=no) | −0.01** (0.00) | −0.01*** (0.00) | −0.01* (0.00) | −0.01** (0.00) |
| Education | −0.00 (0.00) | −0.00* (0.00) | −0.00* (0.00) | −0.00 (0.00) |
| Age | 0.00** (0.00) | 0.00** (0.00) | 0.00** (0.00) | 0.00** (0.00) |
| Last treatment | −0.00 (0.00) | −0.00 (0.00) | −0.00 (0.00) | −0.00 (0.00) |
| Physical comorbidities | −0.00 (0.00) | −0.00 (0.00) | 0.00 (0.00) | −0.00 (0.00) |
| σ intercept | 0.11 | 0.16 | 0.12 | 0.13 |
| ρ intercept, linear | 0.00 | −0.02 | 0.00 | −0.00 |
| σ linear | 0.00 | 0.01 | 0.00 | 0.01 |
| ρ intercept, quadratic | −0.00 | 0.00 | −0.00 | 0.00 |
| ρ linear, quadratic | 0.00 | −0.00 | 0.00 | 0.00 |
| σ quadratic | 0.00 | 0.00 | 0.00 | 0.00 |
| σ residual | 0.05 | 0.05 | 0.05 | 0.05 |
Potential covariates not included due to non-significant prediction: ethnicity, new diagnosis versus recurrence, perceived social status, and body mass index
Est regression coefficient, SE standard error, BCPT Breast Cancer Prevention Trial Symptom Scales, Coping the coping variable used in each model as indicated by the column header, DispAVOID dispositional non-acceptance of emotion, DispAPPROACH dispositional acceptance of emotion, SitAVOID coping through avoidance of the cancer experience, SitAPPROACH coping through approach of the cancer experience
Variable is time varying; all other variables are time invariant
p<0.05
p<0.01
p<0.001